anti-Insulin-Degrading Enzyme (IDE) Antibodies

IDE encodes a zinc metallopeptidase that degrades intracellular insulin, and thereby terminates insulins activity, as well as participating in intercellular peptide signalling by degrading diverse peptides such as glucagon, amylin, bradykinin, and k. Additionally we are shipping Insulin-Degrading Enzyme Kits (58) and Insulin-Degrading Enzyme Proteins (15) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
IDE 15925  
IDE 25700 P35559
IDE 3416 P14735
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-Insulin-Degrading Enzyme Antibodies at antibodies-online.com

Showing 10 out of 156 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Goat Un-conjugated IHC, ELISA, WB ABIN334425 (0.1µg/ml) staining of K562 cell lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. 100 μg Log in to see 6 to 7 Days
$429.84
Details
Cow Rabbit Un-conjugated WB WB Suggested Anti-IDE Antibody   Titration: 1.0 ug/ml   Positive Control: Hela Whole Cell IDE is strongly supported by BioGPS gene expression data to be expressed in Human HeLa cells 100 μL Log in to see 2 to 3 Days
$289.00
Details
Human Goat Biotin ELISA, IHC, WB Biotinylated Antibody (0.3µg/ml) staining of K562 lysate (35µg protein in RIPA buffer), exactly mirroring its parental non-biotinylated product. Primary incubation was 1 hour. Detected by chemiluminescence, using streptavidin-HRP and using NAP blocker as a 100 μg Log in to see 6 to 7 Days
$429.84
Details
Human Rabbit Un-conjugated IHC (p), WB Western blot analysis of anti-IDE Antibody (Center) (ABIN388241) in A375 cell line lysates (35 µg/lane). IDE (arrow) was detected using the purified polyclonal antibody (1:60 dilution). Formalin-fixed and paraffin-embedded human hepatocarcinoma tissue reacted with IDE antibody (Center)(ABIN388241), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. 400 μL Log in to see 10 to 11 Days
$385.00
Details
Mouse Goat Un-conjugated ELISA, WB ABIN190754 (1µg/ml) staining of Mouse Brain lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. 100 μg Log in to see 6 to 7 Days
$429.84
Details
Human Rabbit Un-conjugated IHC, WB Western blot analysis of extracts of various tissues, using IDE antibody. 100 μL Log in to see 11 to 13 Days
$366.77
Details
Human Rabbit Un-conjugated IF (p), IHC (p), WB Formalin-fixed and paraffin-embedded human gastric carcinoma labeled with Rabbit Anti-IDE Polyclonal Antibody, Unconjugated (ABIN723680) at 1:300 followed by conjugation to the secondary antibody and DAB staining Formalin-fixed and paraffin-embedded mouse tumor labeled with Rabbit Anti-IDE Polyclonal Antibody, Unconjugated (ABIN723680) at 1:300 followed by conjugation to the secondary antibody and DAB staining 100 μL Log in to see 3 to 7 Days
$317.90
Details
Human Rabbit Un-conjugated ICC, IHC, WB Figure. Western Blot; Sample: Human HepG2 Cells. 100 μg Log in to see 13 to 16 Days
$332.00
Details
Bat Goat Un-conjugated IHC, IHC (p) Skeletal muscle, Human: Formalin-Fixed, Paraffin-Embedded (FFPE) Prostate, Human: Formalin-Fixed, Paraffin-Embedded (FFPE) 50 μg Log in to see 11 to 14 Days
$484.00
Details
Bat Goat Un-conjugated ELISA, IHC, IHC (p), WB Human Breast: Formalin-Fixed, Paraffin-Embedded (FFPE) Human Lung: Formalin-Fixed, Paraffin-Embedded (FFPE) 50 μg Log in to see 11 to 14 Days
$484.00
Details

Top referenced anti-Insulin-Degrading Enzyme Antibodies

  1. Human Polyclonal IDE Primary Antibody for IHC (p), ELISA - ABIN544069 : Kim, Hersh, Leissring, Ingelsson, Matsui, Farris, Lu, Hyman, Selkoe, Bertram, Tanzi: Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. in The Journal of biological chemistry 2007 (PubMed)
    Show all 3 Pubmed References

  2. Human Polyclonal IDE Primary Antibody for IHC (p), WB - ABIN388241 : Radulescu, Fischer, Stange, Schulze: Promoting scientific standards in Germany. in Science (New York, N.Y.) 2010 (PubMed)
    Show all 6 Pubmed References

  3. Dog (Canine) Polyclonal IDE Primary Antibody for ELISA, WB - ABIN547958 : Zhao, Xiang, Haroutunian, Buxbaum, Stetka, Pasinetti: Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. in Neurobiology of aging 2007 (PubMed)

More Antibodies against Insulin-Degrading Enzyme Interaction Partners

Mouse (Murine) Insulin-Degrading Enzyme (IDE) interaction partners

  1. IDE is not a rate-limiting regulator of plasma insulin levels in vivo.

  2. Study indicated that, in the type 2 diabetes (T2D) and Alzheimer's disease (AD) mice, cAMP/PKA signaling pathway and IDE may participate in the contribute role of T2D in accelerating the pathological process of AD via causing neuronal apoptosis.

  3. Our results found that, in the mice with T2D and AD, the activators of PPARg/AMPK signaling pathway significantly increased the expression level of IDE, and decreased the accumulation of Ab40 and Ab42, as well as alleviated the spatial learning and recognition impairments.

  4. elevated IDE expression, in the skeletal muscle, seems to be mediated by activation of AMPK-ACC pathway, in response to exercise

  5. IDE inhibition did notincrease amyloid formation or beta-cell loss.

  6. This study demonstrated that the Decreased IDE and IGF2 expression in the cerebral cortex of pups by early life lead exposure.

  7. Findings show a key role of Pla2g3 on the reduction of IDE, and suggest that cerebrum specific increase of Pla2g3 is involved in the initiation and/or progression of Alzheimer disease.

  8. Abeta level reduction by CALHM1 could be explained by an increase in extracellular Abeta degradation by insulin-degrading enzyme.

  9. Data suggest that protein restriction down-regulates expression of insulysin (insulin degrading enzyme) in liver and subsequently reduced insulin clearance.

  10. IDE deficiency in bone marrow-derived cells results in larger atherosclerotic lesions, increased lesion-associated Abeta and RAGE, and higher serum cholesterol in male, Ldlr(-/-) mice.

  11. The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of alpha-synuclein levels in beta-cells.

  12. this study identified an upstream promoter element which blocks the reverse transcription of mouse IDE.

  13. Data show that in the absence of insulin-degrading enzyme (IDE), full-length calcitonin gene-related peptide (CGRP) levels are elevated in vivo.

  14. role played by somatostatin in preventing Abeta accumulation by partially restoring IDE activity

  15. These data suggest that NOS2 upregulation impairs amyloid beta degradation through negative regulation of insulin degrading enzyme

  16. BRI2 protein regulates beta-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE).

  17. The diabetic phenotype in IDE-KO mice is not a primary consequence of IDE deficiency, but is instead an emergent compensatory response to chronic hyperinsulinemia resulting from complete deletion of IDE.

  18. The combined data indicate that the non-conventional secretion of IDE is regulated by the newly identified SlyX motif.

  19. Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated IDE.

  20. Proteolytically-active plasma membrane associated-insulin degrading enzyme is routed in living neuroblastoma cells to multivesicular bodies and subsequently, a major fraction is sorted to exosomes.

Human Insulin-Degrading Enzyme (IDE) interaction partners

  1. IDE displays a large opening between the homologous ~55 kDa N- and C-terminal halves to allow selective substrate capture based on size and charge complementarity. Insulin-bound IDE structures explain how IDE processively degrades insulin by stochastically cutting either chain without breaking disulfide bonds.

  2. These results support the hypothesis that IDE gene expression in different areas of Alzheimer's patient's brains.

  3. People with allelic variation in four genes related to cardiovascular diseases and metabolism were more likely to die: apolipoprotein (APO)C1 GG and AG carriers, APOE varepsilon4 carriers, insulin-degrading enzyme (IDE) TC carriers, and phosphatidylinositol 3-kinase (PI3KCB) GG carriers.

  4. Data suggest the possibility of development of insulin-degrading enzyme (IDE)-based drugs for the treatment of the late-onset form of Alzheimer's disease (AD).

  5. the mechanistic and molecular features of IDE-26S proteasome interaction in a cell experimental model, is reported.

  6. No significant associations have been found between other IDE gene single nucleotide polymorphisms of rs4646953, rs2251101 and rs1544210 with Alzheimer disease.

  7. results demonstrate that the polymorphisms rs1887922 and rs1999764 of the IDE gene are associated with late-onset Alzheimer disease susceptibility in the Xinjiang Han population

  8. Cognitive impairment is more frequent among those exposed to the C allele of the rs2209972 SNP of the insulin degrading enzyme gene.

  9. IDE does not play a major role in MHC class I antigen processing, confirming the dominant and almost exclusive role of the proteasome in cytosolic production of MHC class I ligands.

  10. using combinational in silico investigations, study identified that pathogenic nonsynonymous mutations corresponding to p.I54F, p.P122T, p.T533R, p.P581A and p.Y609A have more potential role in structural and functional deviations of IDE activity

  11. Our study provided evidence to IDE, PON1, WFS1, POU2F1, IL1alpha and IL1beta associated with T2D in Pakistanis.

  12. An upstream promoter element which blocks the antisense transcription of the human IDE promoter, was identified.

  13. Both IDE and type 2 diabetes are associated with executive function levels in older adults

  14. Conformational changes in IDE, including a swinging-door mechanism that permits the entry of short peptides into the catalytic chamber, governs the selective destruction of amyloidogenic peptides.

  15. for the rs1832196 polymorphism, significant association with Alzheimer disease was found by the dominant model in overall and subgroup analysis.

  16. In conclusion, this epistatic interaction showed a high degree of consistency when stratifying by sex, the epsilon4 allele of apolipoprotein E genotype, and geographic region.

  17. IDE-Met(1) links the mitochondrial biogenesis pathway with mitAbeta levels and organelle functionality.

  18. Genetic variants for both insulin degrading enzyme (IDE) and angiotensin converting enzyme (ACE) in relation to cognitive phenotype.

  19. In the context of APOEepsilon4-negative status, insulin-degrading enzyme variants are significantly associated with Alzheimer disease in some genetic models.

  20. The polymorphism of insulin-degrading enzyme is associated with susceptibility to Alzheimer's disease in Han Chinese.

Insulin-Degrading Enzyme (IDE) Antigen Profile

Protein Summary

This gene encodes a zinc metallopeptidase that degrades intracellular insulin, and thereby terminates insulins activity, as well as participating in intercellular peptide signalling by degrading diverse peptides such as glucagon, amylin, bradykinin, and kallidin. The preferential affinity of this enzyme for insulin results in insulin-mediated inhibition of the degradation of other peptides such as beta-amyloid. Deficiencies in this protein's function are associated with Alzheimer's disease and type 2 diabetes mellitus but mutations in this gene have not been shown to be causitive for these diseases. This protein localizes primarily to the cytoplasm but in some cell types localizes to the extracellular space, cell membrane, peroxisome, and mitochondrion. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants have been described but have not been experimentally verified.

Gene names and symbols associated with IDE

  • insulin degrading enzyme (IDE) antibody
  • insulin-degrading enzyme (ide) antibody
  • insulin-degrading enzyme (LOC591315) antibody
  • insulin-degrading enzyme (CC1G_01115) antibody
  • insulin-degrading enzyme (Bm1_26615) antibody
  • insulin-degrading enzyme (PTRG_10875) antibody
  • metallopeptidase (SJAG_01430) antibody
  • insulin-degrading enzyme (EBI_21700) antibody
  • insulin-degrading enzyme (VDBG_06702) antibody
  • insulin-degrading enzyme (LOAG_08082) antibody
  • insulin-degrading enzyme (PGTG_04982) antibody
  • insulin-degrading enzyme (Tsp_00424) antibody
  • insulin degrading enzyme (Ide) antibody
  • 1300012G03Rik antibody
  • 4833415K22Rik antibody
  • AA675336 antibody
  • AI507533 antibody
  • IDE antibody
  • INSDEGM antibody
  • INSULYSIN antibody
  • zgc:162603 antibody

Protein level used designations for IDE

insulysin , insulin-degrading enzyme , insulin-degrading enzyme-like , insulin protease , insulinase , Abeta-degrading protease

GENE ID SPECIES
450608 Pan troglodytes
561390 Danio rerio
591315 Strongylocentrotus purpuratus
698640 Macaca mulatta
6009544 Coprinopsis cinerea okayama7130
6100223 Brugia malayi
6349187 Pyrenophora tritici-repentis Pt-1C-BFP
7051385 Schizosaccharomyces japonicus yFS275
8641122 Enterocytozoon bieneusi H348
9537184 Verticillium alfalfae VaMs.102
100071303 Equus caballus
100385143 Callithrix jacchus
100434053 Pongo abelii
100482236 Ailuropoda melanoleuca
9945508 Loa loa
10530847 Puccinia graminis f. sp. tritici CRL 75-36-700-3
10901673 Trichinella spiralis
15925 Mus musculus
25700 Rattus norvegicus
3416 Homo sapiens
477768 Canis lupus familiaris
100341888 Oryctolagus cuniculus
100719651 Cavia porcellus
423814 Gallus gallus
100155309 Sus scrofa
523752 Bos taurus
101104194 Ovis aries
Selected quality suppliers for anti-Insulin-Degrading Enzyme (IDE) Antibodies
Did you look for something else?